Based on the Soleno Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Soleno Therapeutics Inc is USD 88.21 over the next 12 months. Soleno Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Soleno Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Soleno Therapeutics Inc’s stock price was USD 68.93. Soleno Therapeutics Inc’s stock price has changed by -1.53% over the past week, +40.36% over the past month and +83.81% over the last year.
No recent analyst target price found for Soleno Therapeutics Inc
No recent average analyst rating found for Soleno Therapeutics Inc
Company Overview Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Read Less
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet whi...Read More
Frequently Asked Questions About Soleno Therapeutics Inc (SLNO) Stock
Based on ratings from 7 analysts Soleno Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on SLNO's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for SLNO is USD 88.21 over the next 12 months. The maximum analyst target price is USD 123 while the minimum anlayst target price is USD 70.
Unfortunately we do not have enough data on SLNO's stock to indicate if its overvalued.
The last closing price of SLNO's stock was USD 68.93.
The most recent market capitalization for SLNO is USD 3.08B.
Based on targets from 7 analysts, the average taret price for SLNO is projected at USD 88.21 over the next 12 months.
This means that SLNO's stock price may go up by +27.98% over the next 12 months.
We can't find any ETFs which contains Soleno Therapeutics Inc's stock.
As per our most recent records Soleno Therapeutics Inc has 92 Employees.
Soleno Therapeutics Inc's registered address is 100 Marine Parkway, Redwood City, CA, United States, 94065.
You can get more information about it from Soleno Therapeutics Inc's website at https://soleno.life.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Soleno Therapeutics Inc (SLNO) Stock
Based on ratings from 7 analysts Soleno Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on SLNO's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for SLNO is USD 88.21 over the next 12 months. The maximum analyst target price is USD 123 while the minimum anlayst target price is USD 70.
Unfortunately we do not have enough data on SLNO's stock to indicate if its overvalued.
The last closing price of SLNO's stock was USD 68.93.
The most recent market capitalization for SLNO is USD 3.08B.
Based on targets from 7 analysts, the average taret price for SLNO is projected at USD 88.21 over the next 12 months.
This means that SLNO's stock price may go up by +27.98% over the next 12 months.
We can't find any ETFs which contains Soleno Therapeutics Inc's stock.
As per our most recent records Soleno Therapeutics Inc has 92 Employees.
Soleno Therapeutics Inc's registered address is 100 Marine Parkway, Redwood City, CA, United States, 94065.
You can get more information about it from Soleno Therapeutics Inc's website at https://soleno.life.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SLNO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
